US study suggests GLP-1 RA drugs are associated with small increase in ischemic optic neur

US study suggests GLP-1 RA drugs are associated with small increase in ischemic optic neuropathy. A target trial emulation found that people with type 2 diabetes who started glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy had a slightly higher risk of ischemic optic neuropathy (ION), a rare condition involving reduced blood flow to the optic nerve that can cause sudden vision loss, compared with those initiating sodium–glucose cotransporter-2 inhibitors (SGLT2is) or dipeptidyl peptidase-4 inhibitors (DPP4is); however, absolute risk was very low.

A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.

Trechos de apoio da pauta: A target trial emulation found that people with type 2 diabetes who started glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy had a slightly higher risk of ischemic optic neuropathy (ION), a rare condition involving reduced blood flow to the optic nerve that can cause sudden vision loss, compared with those initiating sodium–glucose cotransporter-2 inhibitors (SGLT2is) or dipeptidyl peptidase-4 inhibitors (DPP4is); however, absolute risk was very low.

• Ponto de atenção: study.
• Ponto de atenção: suggests.
• Ponto de atenção: drugs.

Em resumo, a leitura editorial acompanha o impacto do tema no nicho Fitness.